Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Alpha Cognition Inc. (ACOG)

$7.90 -4.01% NASDAQ: ACOG · 15-min delayed
  • GRAPEVINE, Texas
  • Public · NASDAQ: ACOG
  • 71 employees
$126.7MMarket cap
$10.2MRevenue · FY2025
-$20.7MNet income
71Employees
ACOGNASDAQ
2021IPO

About Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$10.2M
Net income
-$20.7M
Total assets
$79.7M
Market cap
$126.7M
Gross margin
94.1%
Operating margin
-221.7%
Net margin
-202.2%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$10.2M
Cost of revenue
$603.4K
Gross profit
$9.6M
Operating expenses
$32.9M
Operating income
-$22.7M
Net income
-$20.7M
EPS (basic)
$-1.17
EPS (diluted)
$-1.18

Balance sheet

Total assets
$79.7M
Current assets
$79.0M
Total liabilities
$17.2M
Current liabilities
$9.1M
Shareholders’ equity
$62.5M

Cash flow

Operating cash flow
-$20.4M
Investing cash flow
-$293.5K
Financing cash flow
$38.2M
Net cash flow
$17.5M

Statements via Polygon.io (SEC filings)

NASDAQ: ACOG
$7.90 -4.01%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$4.50 $11.24

52-week range

Market cap
$126.7M
EPS (diluted)
$-1.18
Shares outstanding
16.0M
Open
Day range
Prev close
Volume
IPO date
Jun 9, 2021

Alpha Cognition Inc. (ACOG) Stock Price

  • Reported a net loss of $20.7M in FY2025.
  • Gross margin of 94.1%, net margin -202.2%.
  • Trading 30% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Alpha Cognition Inc..

Write a review
Newsroom

News about Alpha Cognition Inc.

News & sentiment via Polygon.io

FAQ

Alpha Cognition Inc.: frequently asked questions

Is Alpha Cognition Inc. an American company?

Alpha Cognition Inc. is a US-based company headquartered in Grapevine, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Alpha Cognition Inc. headquartered?

Alpha Cognition Inc. is headquartered in Grapevine, Texas, United States.

Is Alpha Cognition Inc. publicly traded?

Yes — Alpha Cognition Inc. is a publicly traded company. Its stock trades under the ticker symbol ACOG on the NASDAQ.

What does Alpha Cognition Inc. do?

Alpha Cognition Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →